SAN DIEGO, Aug. 3, 2010 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its financial results for the second quarter and six months ended June 30, 2010 before the market opens on Thursday, August 12, 2010.
OccuLogix is pleased to invite all interested parties to participate in a conference call during which the financial results will be discussed. The call will be held on August 12, at 8:30a.m. Eastern Daylight Savings Time at 877-303-6310 (within the United States and Canada).
The call will be broadcast live and archived on the company's web-site at www.tearlab.com under the "webcasts" link in the investor Relations section.
Date: August 12, 2010 Time: 8:30 AM ET
Listen via Internet: http://www.tearlab.com/us/shareholder.htm/
Schedule this webcast into MS-Outlook calendar (click open when prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=43708&k=0016EDAD
Telephone: 877-303-6310
For those wishing to listen to a recording of the call via telephone, a replay will be made available as soon as possible after the conclusion of the live call and will remain posted for a period of seven days. To listen to the recording, simply telephone (Toll free) 800-642-1687 or Toll 706-645-9291 and enter reservation #92168732 when prompted.
About OccuLogix, Inc. dba TearLab Corporation
OccuLogix dba TearLab Corporation (www.tearlab.com) develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'. TearLab received the CE Mark for its TearLab(TM) Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 20 countries including the US.
Forward-Looking Statements
This press release may contain forward-looking statements, including statements regarding the growth of the market for dry eye disease products, the impact of our product on the management of affected patients, and our intention to seek CLIA Waiver. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.